Clinical Trial

A Real-life Observational Study in Severe Eosinophilic Asthma Adult Participant Treated With Benralizumab in Italy

Study acronym: ATHENA
Recruiting
View on ClinicalTrials.gov →
Summary
This is an observational, multicenter, prospective study on patients with severe eosinophilic asthma treated with benralizumab aimed at evaluating the achievement of partial and complete clinical remission.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2025-10-06; most recent amendment 2026-07-07.
Status change: Not Yet Recruiting → Recruiting 2026-01-08
Trial Details
NCT Number NCT07214753
Lead Sponsor AstraZeneca
Conditions Severe Eosinophilic Asthma
Enrollment 335 participants
Start Date 2025-12-20
Primary Completion 2028-12-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-08